Breakeven Date Change • Nov 16
Forecast to breakeven in 2024 The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 08
First half 2022 earnings released First half 2022 results: Net loss: €3.56m (loss widened 13% from 1H 2021). Revenue is forecast to grow 201% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Chemicals industry in France. お知らせ • May 20
Deinove SA, Annual General Meeting, May 30, 2022 Deinove SA, Annual General Meeting, May 30, 2022, at 15:00 Central European Standard Time. Location: 48 rue Cambon Paris France Price Target Changed • Apr 27
Price target decreased to €1.00 Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Major Estimate Revision • Apr 15
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week. Reported Earnings • Apr 14
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Net loss: €6.96m (loss narrowed 4.7% from FY 2020). Revenue exceeded analyst estimates by 19%. Over the next year, revenue is expected to shrink by 33% compared to a 22% growth forecast for the industry in France. お知らせ • Apr 08
Deinove SA Announces the Extension of Its Clinical Trial to Canada Deinove SA announced the extension of its clinical trial to Canada, approved by the Canadian Health authority, with the opening of 5 new sites, complementing those already opened in the United States. This second country will accelerate patient enrollment in this Phase II clinical trial of DNV3837 in Clostridioides difficile infections. The second part of the study will be conducted in an open-label manner. Thus, all 40 patients who will be included in the trial will receive DNV3837. As a reminder, the second part of the trial has been optimized with a reduction in the dose and duration of intravenous administration to 6 hours per day during the 10-day treatment period. This modification simplifies the management of the trial for the investigating physicians and their teams. More than 40% of hospitalized patients with Clostridioides difficile infection (CDI) have been classified as severe disease associated with higher morbidity and mortality1. The Centers for Disease Control and Prevention (CDC) identifies CDI as one of the leading causes of hospital-acquired infections, ahead of even MRSA2 infections. In the United States, it is estimated that CDI causes nearly half a million disease cases each year, and approximately 29,300 deaths3. This condition is not limited to the United States and recent studies4 show that the incidence of this type of infection is greatly underestimated in other parts of the world, such as Europe and Asia. To date, there is no proven therapeutic solution for CDI patients with severe vomiting, ileus and toxic megacolon. The oral route being compromised, the available treatments, which are mostly oral, have difficulty reaching the intestine because of the patient's pathological condition (reduced gastrointestinal motility, intubation, intestinal perforation, etc.), and the few antibiotics that could be administered intravenously do not cross the gastrointestinal barrier and therefore do not reach the infection site. DNV3837 – a prodrug5 of the DNV3681 molecule (also known as MCB3681) – is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria. It is developed as a highly active first-line treatment targeting C. diff. It has demonstrated significant activity and superiority to reference treatments against isolates of C. diff., regardless of their virulence (including the hyper virulent BI/NAP1/027 strain). DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site. Several Phase I trials (on approximately a hundred healthy volunteers) have shown a high concentration of the antibiotic in stools, a strong marker of its presence in the intestine. It has also demonstrated its ability to eliminate Clostridioides bacteria without affecting the gut microbiota. FDA granted the DNV3837 drug with Qualified Infectious Disease Product (QIDP) designation and Fast Track status. お知らせ • Jan 07
Deinove SA Announces A Favorable Opinion from the DSMBfor the Continuation of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile Infections DEINOVE announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI). The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the recruitment in this trial. The experience acquired during this first part of the study has made it possible to improve the trial protocol, with a reduction in dose by a factor of 4 and a reduction in the duration of administration by a factor of 2, reducing the intravenous treatment from 12 to 6 hours per day. This improvement simplifies the management of the trial for the investigating physicians and their teams. The second part of the study will be conducted in an “open-label” manner, as DNV3837 is administered intravenously, while the standards of care are administered orally. Thus, all patients included in the trial (40 in total) will receive DNV3837. To improve patients inclusion in the trial, it was decided to rapidly open new centers in addition to those active in the United States. Reported Earnings • Oct 03
First half 2021 earnings released First half 2021 results: Net loss: €3.15m (loss narrowed 32% from 1H 2020). Reported Earnings • Mar 27
Full year 2020 earnings released The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €836.0k (up 49% from FY 2019). Net loss: €7.30m (loss narrowed 29% from FY 2019). お知らせ • Jan 22
Deinove SA Appoints Hervé Ansanay as Director Deinove SA announces the strengthening of its Business Development team with the appointment of Hervé ANSANAY as Director and Corentin. The recruitment will intensify the implementation of profitable strategic partnerships and the access to non-dilutive financing, to support the development of antimicrobial therapeutic solutions. Hervé ANSANAY brings 20 years experience in accompanying innovative companies and in technology transfer. He was previously Technology Transfer and Business Development Director of the SATT AxLR of Montpellier where he also held the position of Chief Operating Officer. Is New 90 Day High Low • Jan 05
New 90-day high: €0.91 The company is up 50% from its price of €0.61 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Nov 26
New 90-day high: €0.73 The company is up 7.0% from its price of €0.68 on 28 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.58 per share. お知らせ • Nov 20
Deinove SA Signs an Evaluation and Technology Development License with DSM Deinove SA announced the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living. Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement. Is New 90 Day High Low • Oct 26
New 90-day low: €0.54 The company is down 30% from its price of €0.77 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.07 per share. Reported Earnings • Oct 15
First half earnings released Over the last 12 months the company has reported total losses of €9.52m, with losses narrowing by 8.2% from the prior year. 